These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 21417013)

  • 1. [Apolipoprotein C III and hypertriglyceridemia].
    Wang JY
    Sheng Li Ke Xue Jin Zhan; 2010 Feb; 41(1):37-9. PubMed ID: 21417013
    [No Abstract]   [Full Text] [Related]  

  • 2. The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism.
    Luo M; Peng D
    Lipids Health Dis; 2016 Oct; 15(1):184. PubMed ID: 27770802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
    Gouni-Berthold I
    Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia.
    Kypreos KE
    Biochemistry; 2008 Sep; 47(39):10491-502. PubMed ID: 18767813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mendel, molecular biology, and apolipoprotein C-III: a heady combination.
    Patel SB
    Metab Syndr Relat Disord; 2015 Mar; 13(2):55-6. PubMed ID: 25569471
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic epistasis in the VLDL catabolic pathway is associated with deleterious variations on triglyceridemia in obese subjects.
    Brisson D; St-Pierre J; Santuré M; Hudson TJ; Després JP; Vohl MC; Gaudet D
    Int J Obes (Lond); 2007 Aug; 31(8):1325-33. PubMed ID: 17342071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Endogenous hypertriglyceridemia].
    Kotake H; Oikawa S
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():63-8. PubMed ID: 11347144
    [No Abstract]   [Full Text] [Related]  

  • 8. Fat fuels the flame: triglyceride-rich lipoproteins and arterial inflammation.
    Libby P
    Circ Res; 2007 Feb; 100(3):299-301. PubMed ID: 17307968
    [No Abstract]   [Full Text] [Related]  

  • 9. Apolipoprotein C-III: going back to the future for a lipid drug target.
    Huff MW; Hegele RA
    Circ Res; 2013 May; 112(11):1405-8. PubMed ID: 23704213
    [No Abstract]   [Full Text] [Related]  

  • 10. Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies.
    Dib I; Khalil A; Chouaib R; El-Makhour Y; Noureddine H
    Mol Biol Rep; 2021 Jan; 48(1):875-886. PubMed ID: 33389539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triglyceride-rich lipoproteins from normotrygliceridemic subjects and hyperlipidemic patients differently affect endothelial cell activation and gene expression patterns.
    Norata GD; Catapano AL
    Circ Res; 2007 Apr; 100(7):e81. PubMed ID: 17431191
    [No Abstract]   [Full Text] [Related]  

  • 12. Fatty acid-binding protein-2 genotype influences lipid and lipoprotein response to eicosapentaenoic acid supplementation in hypertriglyceridemic subjects.
    Pishva H; Mahboob SA; Mehdipour P; Eshraghian MR; Mohammadi-Asl J; Hosseini S; Karimi F
    Nutrition; 2010; 26(11-12):1117-21. PubMed ID: 20080390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein CIII and highly active antiretroviral therapy (HAART)-induced hypertriglyceridemia.
    Badiou S; Dupuy AM; Baillat V; Fabre J; Tur MD; Cristol JP; Reynes J
    Clin Lab; 2003; 49(1-2):11-3. PubMed ID: 12593470
    [No Abstract]   [Full Text] [Related]  

  • 14. Dietary conjugated linoleic acid induces tissue-specific lipoprotein lipase mRNA modulation in high-sucrose-fed mice.
    Castellanos-Tapia L; Yepiz-Plasencia G; Moya-Camarenaa SY
    Ann Nutr Metab; 2009; 54(2):131-7. PubMed ID: 19339774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.
    Ebara T; Ramakrishnan R; Steiner G; Shachter NS
    J Clin Invest; 1997 Jun; 99(11):2672-81. PubMed ID: 9169497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathogenesis of alcohol-induced hyperlipidemia: case report of hypertriglyceridemia over 10,000 mg%].
    Rahn A; Beigel A; Schmidt FW; Canzler H
    Klin Wochenschr; 1990; 68 Suppl 22():120-2. PubMed ID: 2087070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Determination of potentially atherogenic triglyceride-rich lipoprotein particles].
    Alaupovic P; Blankenhorn DH
    Klin Wochenschr; 1990; 68 Suppl 22():38-42. PubMed ID: 2087077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation.
    Sundaram M; Curtis KR; Amir Alipour M; LeBlond ND; Margison KD; Yaworski RA; Parks RJ; McIntyre AD; Hegele RA; Fullerton MD; Yao Z
    J Lipid Res; 2017 Nov; 58(11):2188-2196. PubMed ID: 28887372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Variation of gene at the apolipoprotein C III locus with the changes of serum lipid profile in school-aged children].
    Zhu W; Feng N; Wang Y
    Wei Sheng Yan Jiu; 2002 Aug; 31(4):241-3. PubMed ID: 12600028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein CIII: a link between hypertriglyceridemia and vascular dysfunction?
    Caron S; Staels B
    Circ Res; 2008 Dec; 103(12):1348-50. PubMed ID: 19059836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.